Literature DB >> 32062714

Inpatient Mortality Benefit with Transjugular Intrahepatic Portosystemic Shunt for Hospitalized Hepatorenal Syndrome Patients.

Paris Charilaou1, Kalpit Devani2, Romela Petrosyan3, Chakradhar Reddy2, Nikolaos Pyrsopoulos4.   

Abstract

BACKGROUND: It has been reported that transjugular intrahepatic portosystemic shunting (TIPS) might be utilized as a salvage option for hepatorenal syndrome (HRS), while randomized controlled trials are pending and real-world contemporary data on inpatient mortality is lacking.
METHODS: We conducted an observational retrospective cohort study from the National Inpatient Sample from 2005 to 2014. We included all adult patients admitted with HRS and cirrhosis, using ICD 9-CM codes. We excluded cases with variceal bleeding, Budd-Chiari, end-stage renal disease, liver transplant and transfers to acute-care facilities. TIPS' association with inpatient mortality was assessed using multivariable mixed-effects logistic regression, as well as exact-matching, thus mitigating for TIPS selection bias. The exact-matched analysis was repeated among TIPS-only versus dialysis-only patients.
RESULTS: A total of 79,354 patients were included. Nine hundred eighteen (1.2%) underwent TIPS. Between TIPS and non-TIPS groups, mean age (58 years) and gender (65% males) were similar. Overall mortality was 18% in TIPS and 48% in dialysis-only cases (n = 10,379; 13.1%). Ninety six (10.5%) TIPS patients underwent dialysis. In-hospital mortality in TIPS patients was twice less likely than in non-TIPS patients (adjusted odds ratio [aOR] = 0.43, 95% CI 0.30-0.62; p < 0.001), with similar results in matched analysis [exact-matched (em) OR = 0.39, 95% CI 0.17-0.89; p < 0.024; groups = 96; unweighted n = 463]. Head-to-head comparison showed that TIPS-only patients were 3.3 times less likely to succumb inpatient versus dialysis-only patients (contrast aOR = 0.31, 95% CI 0.20-0.46; p < 0.001), with similar findings post-matching (emOR = 0.22, 95% CI 0.15-0.33; p < 0.001; groups = 54, unweighted n = 1457).
CONCLUSIONS: Contemporary, real-world data reveal that TIPS on its own, and when compared to dialysis, is associated with decreased inpatient mortality when utilized in non-bleeders-HRS patients. Further randomized studies are needed to establish the long-term benefit of TIPS in these patients.

Entities:  

Keywords:  HRS; Hepatorenal syndrome; Inpatient mortality; Matched; NIS; Nationwide; Tips; Transjugular intrahepatic portosystemic shunt

Mesh:

Year:  2020        PMID: 32062714     DOI: 10.1007/s10620-020-06136-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  5 in total

1.  Transjugular Intrahepatic Porto Systemic Shunt for Hepatorenal Syndrome in Alcoholic Patients.

Authors:  Gianni Testino
Journal:  Dig Dis Sci       Date:  2020-04-13       Impact factor: 3.199

Review 2.  Management of Portal Hypertension.

Authors:  Anand V Kulkarni; Atoosa Rabiee; Arpan Mohanty
Journal:  J Clin Exp Hepatol       Date:  2022-03-21

Review 3.  The role of transjugular intrahepatic portosystemic shunt in patients with portal hypertension: Advantages and pitfalls.

Authors:  Hae Lim Lee; Sung Won Lee
Journal:  Clin Mol Hepatol       Date:  2021-09-27

4.  In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample.

Authors:  Wisit Kaewput; Charat Thongprayoon; Carissa Y Dumancas; Swetha R Kanduri; Karthik Kovvuru; Chalermrat Kaewput; Pattharawin Pattharanitima; Tananchai Petnak; Ploypin Lertjitbanjong; Boonphiphop Boonpheng; Karn Wijarnpreecha; Jose L Zabala Genovez; Saraschandra Vallabhajosyula; Caroline C Jadlowiec; Fawad Qureshi; Wisit Cheungpasitporn
Journal:  World J Gastroenterol       Date:  2021-12-07       Impact factor: 5.742

Review 5.  Transjugular intrahepatic portosystemic shunt in cirrhosis: An exhaustive critical update.

Authors:  Sasidharan Rajesh; Tom George; Cyriac Abby Philips; Rizwan Ahamed; Sandeep Kumbar; Narain Mohan; Meera Mohanan; Philip Augustine
Journal:  World J Gastroenterol       Date:  2020-10-07       Impact factor: 5.742

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.